How best to manage patients who present with ductal carcinoma in situ (DCIS), a noninvasive and early form of breast cancer, remains unclear. Treatment options range from minimal, breast-conserving surgical intervention and no follow-up treatment, to surgical intervention followed by additional treatment.
It used to be so easy. Patients with ER-positive breast cancer got 5 years of tamoxifen. You could anticipate most of the side effects. No one showed up with an armload of internet downloads ready to debate the utility of hormone therapy, the risks, and metabolism or drug interactions. No more.
As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.
New technologies and techniques are in development to use blood samples to detect biological material in the blood that can differentiate a patient with cancer from one who does not have cancer and to aid in the treatment of breast cancer patients.
A new study by researchers at the Scripps Research Institute has identified a metabolic mechanism by which breast tumor cells control tumor aggressiveness.
The FDA has approved ado-trastuzumab emtansine (Kadcyla), known as T-DM1 in development, for the treatment of women with metastatic HER2-positive breast cancer.
The prospect of even more compressed radiotherapy options for women requiring adjuvant breast radiotherapy is exciting. However, we urge readers to be cautious in their interpretation of the current intraoperative literature as they implement their programs.
Due to the fact that we do not have mature long-term data regarding efficacy, we are still several years away from declaring IORT to be a viable alternative to the current standard of care in patients with early-stage breast cancer.
With many centers seeking to adopt IORT, there are licensing, proctoring, staffing, technical support, and reimbursement issues that need to be considered. We have reviewed the current international experience and describe one community cancer center’s experience with initiating an IORT breast cancer program.
Consuming more vegetables is associated with a lower risk of estrogen receptor (ER)-negative breast cancer, according to a new study published in the Journal of the National Cancer Institute.
Researchers discovered that in triple-negative breast cancer, an inhibitor of metastasis, miR-708, is repressed, results that could lead to novel therapies.
An analysis of 164 phase III breast cancer trials shows bias in reporting the primary endpoint and toxicity results, according to results of a recent study.
Such a systematic review of the current status of mTOR inhibitors in the treatment of breast cancer demonstrates holes in our knowledge of the role of the tumor, the host, and metabolic factors in breast cancer progression.
Efforts to identify clinical biomarkers of response or resistance to mTOR inhibitors are ongoing. This review will summarize results of preclinical and clinical studies as well as ongoing clinical trials with mTOR or dual PI3K/mTOR inhibitors.
Knowing the genetic makeup of patient tumors permits the development of new DNA-based diagnostics, such as BEAMing and PARE. By incorporating these new tools into future trials, we should be able to concurrently learn about drug resistance and significantly improve patient responses.
The risk of triple-negative breast cancer appears to be lower for women who delayed childbirth and who chose to breast feed according to a new study.
Women who have higher levels of pigments found in fruits and vegetables called carotenoids may have a lower risk of breast cancer. This inverse relationship was found to be particularly strong for more lean women, those with ER-negative tumors, and current smokers.
Scientists have identified a novel way metastatic breast cancer cells can bypass targeted therapy. Breast cancer cells with an active PI3K/mTOR pathway treated with a PI3K inhibitor are able to turn up a different pathway, the Janus family of kinases, and continue to grow.
Triple-negative breast cancer patients with primary invasive cancer did not benefit from adjuvant combination chemotherapy plus bevacizumab compared to chemotherapy alone.
Combining histone deacetylase (HDAC) inhibitors with PARP inhibitors or cisplatin has the potential to be an effective treatment for triple-negative breast cancer, according to preclinical research presented this week at the San Antonio Breast Cancer Symposium.
A small study analyzing neurocognitive function in women undergoing chemotherapy to treat their breast cancer shows that some of the common cognitive issues experienced by breast cancer patients tend to occur not only post-chemotherapy, but also prior to chemotherapy treatment.
Combining an investigational agent called PD 0332991 with letrozole improved progression-free survival over letrozole alone in women with advanced estrogen receptor-positive breast cancer, according to a study presented at the San Antonio Breast Cancer Symposium this week.
A large cohort study found that black women with early-stage invasive breast cancer were significantly less likely than white patients to undergo the less invasive axillary sentinel lymph node biopsy. Black women also had a higher rate of lymphedema, due largely to that difference in treatment modalities.
Increasing the dose of fulvestrant from 250 mg to 500 mg yielded a longer median overall survival as well as a lower overall risk of death in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to results from the CONFIRM trial.
Breast cancer patients 35 years and younger, even those with luminal-like disease, derive more benefit from neoadjuvant chemotherapy than do older patients, according to a German study presented at SABCS.
